Biogen | BIIB - Betriebsergebnis

Aktienkurs
172.97
Täglich Wechseln
-4.14 -2.34%
Monatlich
-9.19%
Jährlich
50.19%
Q2 Prognose
168.25




Betriebsergebnis Veränderung Datum
AbbVie USD 5.81B 1.23B 2025-12
Acadia Pharmaceuticals USD 17.39M 18.36M 2025-12
ALKERMES USD -10.95M 100.03M 2025-12
Amgen USD 3.96B 464M 2025-12
Bayer EUR 1.11B 1.65B 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Merck USD 6.24B 318M 2025-12
Moderna USD -857M 597M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novartis USD 4.06B 437M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Puma Biotechnology USD 22.08M 24.26M 2024-09
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sanofi EUR 1.7B 2.17B 2025-12
Sanofi EUR 1.5B 2.29B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Teva Pharmaceutical Industries USD 487M 581M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
United Therapeutics USD -14.6M 403.9M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12